keyword
MENU ▼
Read by QxMD icon Read
search

Cancer related anemia

keyword
https://www.readbyqxmd.com/read/29778393/fertility-preservation-in-pediatric-female-cancer-patients
#1
Sara E Arian, Rebecca L Flyckt, Richard Herman, Hadi Erfani, Tommaso Falcone
OBJECTIVE: To describe and demonstrate ovarian tissue cryopreservation (OTC) as an emerging fertility preservation technique DESIGN: Video presentation. SETTING: University hospital. PATIENT(S): A 6 year-old female patient diagnosed with aplastic anemia with plan for bone marrow transplantation underwent laparoscopic unilateral oophorectomy in conjunction with surgical procedure for port placement by the pediatric surgeon, followed by cryopreservation of ovarian tissue...
May 2018: Fertility and Sterility
https://www.readbyqxmd.com/read/29768958/bevacizumab-induced-atypical-hemolytic-uremic-syndrome-and-treatment-with-eculizumab
#2
Anusha Vakiti, Daulath Singh, Ravi Pilla, Muhamad A Moustafa, Kelly W Fitzpatrick
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the management of various solid malignancies including colorectal, lung, brain, renal, and ovarian cancers as well as age-related macular degeneration of the eye. It is a vascular endothelial growth factor inhibitor which exhibits its action by blocking the growth of blood vessels in cancerous tissue. Common side effects include hypertension, fatigue, headaches, and increased risk of infections. Atypical hemolytic uremic syndrome is a serious side effect associated with bevacizumab due to its anti-angiogenic effect...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29764591/-clinical-analysis-of-small-cell-lung-cancer-with-bone-marrow-metastases
#3
Yiqun Che, Yang Luo, Di Wang, Di Shen, Lin Yang
BACKGROUND: Small cell lung cancer (SCLC) is highly malignant and prone to bone marrow metastasis in early stage, but its related reports are limited. This study analyzed the clinical feature, laboratory examination, treatment and prognosis of SCLC patients with bone marrow metastasis. METHODS: The clinical data of 26 SCLC patients with bone marrow metastasis were analyzed retrospectively. Prognostic factors were evaluated. RESULTS: The median age of 26 patients was 57 years and the median time from diagnosis of SCLC to confirmed bone marrow metastases was 8 d...
May 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29744674/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-women-with-estrogen-receptor-positive-or-triple-negative-breast-cancer
#4
Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L Blackwell, Lisa A Carey, Joel R Eisner, Edwina S Baskin-Bey, Tiffany A Traina
PURPOSE: Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK), and activity of once-daily (QD) seviteronel in women with locally advanced or metastatic TNBC or ER+ breast cancer. METHODS: Seviteronel was administered in de-escalating 750, 600, and 450 mg QD 6-subject cohorts...
May 9, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29742009/multicenter-prospective-phase-ii-trial-of-neoadjuvant-dose-dense-gemcitabine-plus-cisplatin-in-patients-with-muscle-invasive-bladder-cancer
#5
Gopa Iyer, Arjun V Balar, Matthew I Milowsky, Bernard H Bochner, Guido Dalbagni, S Machele Donat, Harry W Herr, William C Huang, Samir S Taneja, Michael Woods, Irina Ostrovnaya, Hikmat Al-Ahmadie, Maria E Arcila, Jamie C Riches, Andreas Meier, Caitlin Bourque, Maha Shady, Helen Won, Tracy L Rose, William Y Kim, Brooke E Kania, Mariel E Boyd, Catharine K Cipolla, Ashley M Regazzi, Daniela Delbeau, Asia S McCoy, Hebert Alberto Vargas, Michael F Berger, David B Solit, Jonathan E Rosenberg, Dean F Bajorin
Purpose Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of care for the management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin-based regimens have yielded favorable outcomes compared with standard-dose chemotherapy, yet the optimal neoadjuvant regimen remains undefined. We assessed the efficacy and tolerability of six cycles of neoadjuvant dose-dense gemcitabine and cisplatin (ddGC) in patients with MIBC. Patients and Methods In this prospective, multicenter phase II study, patients received ddGC (gemcitabine 2,500 mg/m2 on day 1 and cisplatin 35 mg/m2 on days 1 and 2) every 2 weeks for 6 cycles followed by RC...
May 9, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29737372/efficacy-and-safety-of-cytotoxic-drug-chemotherapy-after-first-line-egfr-tki-treatment-in-elderly-patients-with-non-small-cell-lung-cancer-harboring-sensitive-egfr-mutations
#6
Hisao Imai, Hiroyuki Minemura, Tomohide Sugiyama, Yutaka Yamada, Kyoichi Kaira, Kenya Kanazawa, Takashi Kasai, Takayuki Kaburagi, Koichi Minato
PURPOSE: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is effective as first-line chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive EGFR mutations. However, whether the efficacy of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment is similar to that of first-line cytotoxic drug chemotherapy in elderly patients aged ≥ 75 years harboring sensitive EGFR mutations is unclear. Therefore, we aimed to investigate the efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations...
May 8, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29733524/safety-and-pharmacokinetics-of-veliparib-extended-release-in-patients-with-advanced-solid-tumors-a-phase-i-study
#7
Theresa L Werner, Jasgit Sachdev, Elizabeth M Swisher, Martin Gutierrez, Muaiad Kittaneh, Mark N Stein, Hao Xiong, Martin Dunbar, Danielle Sullivan, Philip Komarnitsky, Mark McKee, Antoinette R Tan
The poly(ADP-ribose) polymerase-1/2 inhibitor veliparib is active against tumors deficient in homologous DNA damage repair. The pharmacokinetics and safety of veliparib extended-release (ER) were evaluated in patients with advanced solid tumors. This phase I study assessed veliparib-ER up to 800 mg once daily or 600 mg twice daily. Dose-limiting toxicities (DLTs), recommended phase II dose (RP2D), and maximum tolerated dose (MTD) were assessed in cycle 1 and safety/tolerability during continuous administration (28-day cycles)...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29731841/the-potential-function-of-micrornas-as-biomarkers-and-therapeutic-targets-in-multiple-myeloma
#8
REVIEW
Bingying Zhu, Shaoqing Ju, Haidan Chu, Xianjuan Shen, Yan Zhang, Xi Luo, Hui Cong
Multiple myeloma (MM), accounting for ~1% of all types of human cancer and 13% of all hematological malignancies, is characterized by the malignant proliferation of monoclonal plasma cells (PCs) in the bone marrow. MM leads to end stage organ impairment, including bone lesions, renal dysfunction, hypercalcemia and anemia. So far, the specific pathogenesis of MM remains unclear and no early-stage sensitive biomarker of MM has been well characterized. Furthermore, treating MM is difficult, as the majority of patients eventually relapse or become refractory following treatment using presently available methods...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29724300/evaluation-of-the-safety-of-ramucirumab-in-japanese-patients-with-advanced-gastric-cancer
#9
M Iwai, D Ito, H Asano, S Adachi, K Okada, M Kimura, E Usami, K Matsuo, T Yoshimura, H Teramachi
As a result of the RAINBOW trial, ramucirumab plus paclitaxel was established as a second-line treatment of advanced gastric cancer. Regarding the safety of ramucirumab plus paclitaxel in the Japanese, a subgroup analysis of the RAINBOW trial was conducted. The incidence of neutropenia was higher in Japanese patients. However, information is lacking concerning the safety of ramucirumab after marketing in Japanese patients. Therefore, the aim of this study was to evaluate the safety of ramucirumab in Japanese patients with advanced gastric cancer...
May 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29723676/towards-optimal-intraoperative-conditions-in-esophageal-surgery-a-review-of-literature-for-the-prevention-of-esophageal-anastomotic-leakage
#10
REVIEW
Boukje Titia Bootsma, Daitlin Esmee Huisman, Victor Dirk Plat, Linda Jeanne Schoonmade, Jurre Stens, Guy Hubens, Donald Leonard van der Peet, Freek Daams
BACKGROUND: Esophageal anastomotic leakage (EAL) is a severe complication following gastric and esophageal surgery for cancer. Several non-modifiable, patient or surgery related risk factors for EAL have been identified, however, the contribution of modifiable intraoperative parameters remains undetermined. This review provides an overview of current literature on potentially modifiable intraoperative risk factors for EAL. MATERIALS AND METHODS: The PubMed, EMBASE and Cochrane databases were searched by two researchers independently...
April 30, 2018: International Journal of Surgery
https://www.readbyqxmd.com/read/29721386/in-situ-delivery-of-allogeneic-natural-killer-cell-nk-combined-with-cetuximab-in-liver-metastases-of-gastrointestinal-carcinoma-a-phase-i-clinical-trial
#11
O Adotevi, Y Godet, J Galaine, Z Lakkis, I Idirene, J M Certoux, M Jary, R Loyon, C Laheurte, S Kim, A Dormoy, F Pouthier, C Barisien, F Fein, P Tiberghien, X Pivot, S Valmary-Degano, C Ferrand, P Morel, E Delabrousse, C Borg
Despite successful introduction of NK-based cellular therapy in the treatment of myeloid leukemia, the potential use of NK alloreactivity in solid malignancies is still elusive. We performed a phase I clinical trial to assess the safety and efficacy of in situ delivery of allogeneic NK cells combined with cetuximab in liver metastasis of gastrointestinal origin. The conditioning chemotherapy was administrated before the allogeneic NK cells injection via hepatic artery. Three escalating doses were tested (3...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29712865/mechanism-for-survival-of-homozygous-nonsense-mutations-in-the-tumor-suppressor-gene-brca1
#12
Aaron Seo, Orna Steinberg-Shemer, Sule Unal, Silvia Casadei, Tom Walsh, Fatma Gumruk, Stavit Shalev, Akiko Shimamura, Nurten Ayse Akarsu, Hannah Tamary, Mary-Claire King
BRCA1 is essential for repair of DNA double-strand breaks by homologous recombination, and hence for survival. Complete loss of its function is lethal during early embryonic development. Patients who are compound heterozygous for BRCA1 truncating mutations and missense alleles that retain some DNA repair capacity may survive, albeit with very high risk of early onset breast or ovarian cancer and features of Fanconi anemia. However, a mechanism enabling survival of patients homozygous for BRCA1 truncating mutations has not been described...
April 30, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29703819/new-insights-from-studies-of-clonal-hematopoiesis
#13
Christopher J Gibson, David P Steensma
Clonal hematopoiesis (CH) describes an asymptomatic expansion of blood cells descended from a single hematopoietic stem cell. Recent studies have shown that CH increases in frequency with aging, and is often driven by somatic mutations in genes that are recurrently mutated in hematologic malignancies. When CH is associated with a mutation in a leukemia-associated gene at a variant allele frequency of 0.02 or greater, it is termed "clonal hematopoiesis of indeterminate potential" (CHIP).  CHIP has a 0...
April 27, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29691561/-evaluation-of-nutrition-risk-and-analysis-of-relative-factors-of-patients-with-oral-and-maxillofacial-cancer
#14
Ying Liu, Wu-Long Jin
PURPOSE: To evaluate the potential nutrition risk and analyze relative factors in patients with oral and maxillofacial cancer, and explore the treatment method of nutrition risk. METHODS: Eighty eight patients with oral and maxillofacial cancer were included in the present study. Their age, height, weight, clinical classification, level of hemoglobin、albumin and prealbumin,present treatment were recorded and patients' body weight index (BMI) was calculated and scored based on a table of nutrition risk evaluation...
December 2017: Shanghai Kou Qiang Yi Xue, Shanghai Journal of Stomatology
https://www.readbyqxmd.com/read/29675680/a-randomized-double-blind-phase-2-study-of-ruxolitinib-or-placebo-in-combination-with-capecitabine-in-patients-with-advanced-her2-negative-breast-cancer-and-elevated-c-reactive-protein-a-marker-of-systemic-inflammation
#15
Joyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma, Paul Richards, Denise A Yardley, Gail Shaw Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan Geschwindt, Wei Jiang, Hope S Rugo
PURPOSE: The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1). METHODS: Patients with ≤ 2 prior chemotherapy regimens for advanced or metastatic disease or hormone receptor-positive patients with disease progression on prior hormonal therapies were randomized 1:1 to 21-day cycles of ruxolitinib (n = 76) or placebo (n = 73) plus capecitabine...
April 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29674506/diagnostic-and-prognostic-roles-of-circulating-exosomal-micrornas-in-acquired-aplastic-anemia-and-myelodysplastic-syndromes
#16
Valentina Giudice, Lauren G Banaszak, Fernanda Gutierrez-Rodrigues, Sachiko Kajigaya, Reema Panjwani, Maria Del Pilar Fernandez Ibanez, Olga Rios, Christopher K Bleck, Erin S Stempinski, Diego Quinones Raffo, Danielle M Townsley, Neal S Young
Exosomal microRNAs modulate cancer cell metabolism and the immune response. Specific exosomal microRNAs have been reported to be reliable biomarkers of several solid and hematologic malignancies. We examined the possible diagnostic and prognostic values of exosomal microRNAs in two human bone marrow failure diseases, aplastic anemia and myelodysplastic syndromes. After screening of 372 microRNAs in a discovery set (n=42) of plasma exosome samples, we constructed a custom microRNA PCR plate, including 42 microRNAs, for validation in a larger cohort (n=99), and we identified 25 differentially expressed exosomal microRNAs uniquely or frequently present in aplastic anemia and/or myelodysplastic syndromes...
April 19, 2018: Haematologica
https://www.readbyqxmd.com/read/29674498/microenvironmental-m1-tumor-associated-macrophage-polarization-influences-cancer-related-anemia-in-advanced-ovarian-cancer-key-role-of-interleukin-6
#17
Clelia Madeddu, Giulia Gramignano, Paraskevas Kotsonis, Ferdinando Coghe, Vinicio Atzeni, Mario Scartozzi, Antonio Macciò
No abstract text is available yet for this article.
April 19, 2018: Haematologica
https://www.readbyqxmd.com/read/29672628/derivation-and-internal-validation-of-a-mortality-risk-index-for-aged-people-living-with-hiv-the-dat-aids-score
#18
Maxime Hentzien, Cyrille Delpierre, Pascal Pugliese, Clotilde Allavena, Christine Jacomet, Marc-Antoine Valantin, André Cabié, Lise Cuzin, David Rey, Firouzé Bani-Sadr, Moustapha Dramé
OBJECTIVE: The objective was to develop a multivariable prognostic index for overall mortality over a five-year span integrating classical HIV biomarkers and comorbidities in people living with HIV (PLHIV) aged 60 or older. DESIGN: Prospective multicenter cohort study from the French Dat'AIDS cohort. METHODS: All HIV-1 infected patients aged 60 years or older on 1st January 2008 were included. Sociodemographic data, CD4 cell count, CD4 nadir, HIV viral load, history of comorbidities, hepatitis co-infections and laboratory parameters at baseline were considered as potential prognostic variables...
2018: PloS One
https://www.readbyqxmd.com/read/29670374/multiline-treatment-combining-apatinib-with-toptecan-for-platinum-resistant-recurrent-ovarian-cancer-patients-a-report-of-three-cases
#19
Yuan Cheng, Juan Zhang, Haiyun Geng, Shukui Qin, Haiqing Hua
The aim of this study was to observe the efficacy and safety of apatinib combined with toptecan therapy in the multiline treatment of platinum-resistant recurrent ovarian cancer patients. The clinical records of three patients with platinum-resistant recurrent ovarian cancer treated with apatinib combined with toptecan therapy were analyzed and followed up for 3 months, and the related literatures were reviewed. The three patients achieved partial response and the tumor marker CA125 levels decreased significantly as an outcome of the treatment...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29663669/preliminary-efficacy-and-tolerability-of-chemohormonal-therapy-in-metastatic-hormone-na%C3%A3-ve-prostate-cancer-the-first-real-life-experience-in-asia
#20
Darren M C Poon, Tim Chan, Kuen Chan, Michelle Chan, Eric K C Lee, Kitty Law, Daisy Lam
INTRODUCTION: A substantial survival benefit with chemohormonal therapy has been proven by the CHAARTED and STAMPEDE studies, and this clinical approach has emerged as the standard of care for patients with metastatic hormone-naïve prostate cancer (mHSPC). However, because its clinical efficacy and tolerability in Asian patients remains uncertain, this study aims to evaluate preliminary results of its use in Hong Kong. METHODS: The clinical records of mHSPC patients treated with chemohormonal therapy from all six public oncology centers in Hong Kong between January 2015 and July 2016 were reviewed...
April 16, 2018: Asia-Pacific Journal of Clinical Oncology
keyword
keyword
34939
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"